Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Regeneron Pharmaceuticals ( REGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.6%. By the end of trading, Regeneron Pharmaceuticals fell $4.14 (-1.9%) to $215.47 on heavy volume. Throughout the day, 2,404,007 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,160,400 shares. The stock ranged in price between $212.82-$226.00 after having opened the day at $220.95 as compared to the previous trading day's close of $219.61. Other companies within the Drugs industry that declined today were: Idenix Pharmaceuticals ( IDIX), down 30.7%, Genvec ( GNVC), down 17.4%, Biosante Pharmaceuticals ( BPAX), down 16.7% and Fibrocell Science ( FCSC), down 16.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $22.2 billion and is part of the health care sector. The company has a P/E ratio of 30.7, above the S&P 500 P/E ratio of 17.7. Shares are up 35.3% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Oramed Pharmaceuticals ( ORMP), down 25.6%, Cytokinetics ( CYTK), down 22.0%, Novogen ( NVGN), down 18.9% and Immunomedics ( IMMU), down 16.2% , were all gainers within the drugs industry with Merck ( MRK) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null